Publication | Closed Access

CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

Cancer ImmunosurveillanceMedicineImmunologyTumor Growth InhibitionImmune Checkpoint InhibitorImmune Checkpoints Pd-l1ImmunotherapyOncologyRadiation OncologyPhase 1